Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Bruce Green"'
Autor:
Bruce Green
Publikováno v:
Oñati Socio-Legal Series, Vol 7, Iss 4, Pp 790-808 (2017)
In the US, courts widely perceive that judicial scarcity is a common problem threatening the fair and timely resolution of disputes. Courts cite the attendant interest in judicial economy to justify interpreting the procedural and substantive law to
Externí odkaz:
https://doaj.org/article/a209bbf8ced44070923b70f45fd4b5ca
Publikováno v:
Current Drug Metabolism. 21:746-750
Background: In vitro-in vivo extrapolation (IVIVE) of hepatic drug clearance (CL) involves the scaling of hepatic intrinsic clearance (CLint,uH) by functional liver size, which is approximated by total liver volume (LV) as per the convention. However
Autor:
Rukshana Shroff, Bruce Green, Sumithra Selvam, Jyoti Sharma, Greta Rait, Mandy Wan, Jyoti Singhal, Nivedita Kamath, Susan Uthup, Arpana Iyengar, Hamsa V. Reddy, Jignesh P. Patel, Sudha Ekambaram
Publikováno v:
Wan, M, Green, B, Iyengar, A, Kamath, N, Reddy, H, Sharma, J, Singhal, J, Uthup, S, Ekambaram, S, Selvam, S, Rait, G, Shroff, R & Patel, J 2022, ' Population pharmacokinetics and dose optimisation of colecalciferol in paediatric patients with chronic kidney disease ', British Journal of Clinical Pharmacology, vol. 88, no. 3, doi.org/10.1111/bcp.15064, pp. 1223-1234 . https://doi.org/10.1111/bcp.15064
AIMS: The prevalence of vitamin D deficiency is high in children with chronic kidney disease (CKD). However, current dosing recommendations are based on limited pharmacokinetic (PK) data. This study aimed to develop a population PK model of colecalci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4160726f144ced16816bd5f9cc488f0e
https://kclpure.kcl.ac.uk/en/publications/cb198942-c275-4a6a-96bc-169031b6b3f2
https://kclpure.kcl.ac.uk/en/publications/cb198942-c275-4a6a-96bc-169031b6b3f2
Autor:
Alexander Brown, Bradley Ferguson, Bruce Green, Justin Pearre, Ifeoma Anunoby, Carmen M. Cirstea
Publikováno v:
2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM).
Publikováno v:
Clinical Pharmacokinetics. 59:475-483
Fat-free mass has gained wide acceptance as a scaler of the maintenance dose rate in obese patients. The choice of fat-free mass as a size scaler for the maintenance dose rate is based on its relationship with drug clearance, on the basis that only l
Autor:
Bruce Green, Anna Gazes, Alison Brown, Jignesh P. Patel, Emma Gee, John K. Bartoli-Abdou, Julia Czuprynska, Roopen Arya, Raj K. Patel, Valerie Scott, Sarah Woolcombe, Lara N. Roberts, Sinead Duffy, Victoria Speed, Sarah Barsam, R. K. Patel, Bipin Vadher, Rosalind Byrne
Publikováno v:
Speed, V, Green, B, Roberts, L N, Woolcombe, S, Bartoli-abdou, J, Barsam, S, Byrne, R, Gee, E, Czuprynska, J, Brown, A, Duffy, S, Vadher, B, Patel, R, Scott, V, Gazes, A, Patel, R K, Arya, R & Patel, J P 2020, ' Fixed dose rivaroxaban can be used in extremes of bodyweight: a population pharmacokinetic analysis ', Journal of Thrombosis and Haemostasis, vol. 18, no. 9, pp. 2296-2307 . https://doi.org/10.1111/jth.14948
Background: Emerging safety and efficacy data for rivaroxaban suggest traditional therapy and rivaroxaban are comparable in the morbidly obese. However, real-world data that indicate pharmacokinetic (PK) parameters are comparable at the extremes of b
Publikováno v:
European Journal of Clinical Pharmacology. 74:593-599
Schizophrenia is a common disease which is commonly managed using antipsychotic medications (APS). Inadequate response and lack of adherence often prevent optimal therapeutic effectiveness. Monitoring APS concentrations can be useful to help improve
Publikováno v:
European Journal of Pharmaceutical Sciences. 109:S154-S160
Respiratory syncytial virus (RSV) causes acute lower respiratory tract infections, and is a major cause of hospital admissions and death in young children. Limited treatments currently exist that can prevent or minimise exacerbation of the disease. T
Autor:
Rajesh Patel, Roopen Arya, Lara N. Roberts, Bruce Green, Venu Kavarthapu, Sarah Barsam, Jignesh P. Patel
Publikováno v:
Research and Practice in Thrombosis and Haemostasis
Barsam, S J, Patel, J P, Roberts, L, Kavarthapu, V, Patel, R, Green, B & Arya, R 2017, ' The impact of body weight on rivaroxaban pharmacokinetics ', Research and Practice in Thrombosis and Haemostasis, vol. 1, pp. 180-187 . https://doi.org/10.1002/rth2.12039
Barsam, S J, Patel, J P, Roberts, L, Kavarthapu, V, Patel, R, Green, B & Arya, R 2017, ' The impact of body weight on rivaroxaban pharmacokinetics ', Research and Practice in Thrombosis and Haemostasis, vol. 1, pp. 180-187 . https://doi.org/10.1002/rth2.12039
EssentialsThe optimal dosing strategy of rivaroxaban for patients at the extremes of body weight is not known.A pharmacokinetic study was conducted based in real-world patients in a London teaching hospital.In the cohort of patients studied, weight o
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 6:589-595
Schizophrenia is a common disease managed by a range of interventions, with the primary treatment being antipsychotic medications (APS). Inadequate response, lack of adherence, and/or adverse events often prevent optimal therapeutic effects or therap